The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention
Viruses · 2024
DOI: 10.3390/v16060911 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2024. Verfasst von Jannifer Jasmin Thavarajah und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health, Aarhus University, 8000 Aarhus C, Denmark. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, HIV Antibodies, Antibodies, Neutralizing. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Danmarks Frie Forskningsfond, Independent Research Fund Denmark.
Abstract (Originalsprache)
Background
Although antiretroviral therapy (ART) effectively halts disease progression in HIV infection, the complete eradication of the virus remains elusive. Additionally, challenges such as long-term ART toxicity, drug resistance, and the demanding regimen of daily and lifelong adherence required by ART highlight the imperative need for alternative therapeutic and preventative approaches. In recent years, broadly neutralizing antibodies (bNAbs) have emerged as promising candidates, offering potential for therapeutic, preventative, and possibly curative interventions against HIV infection.
Objective
This review aims to provide a comprehensive overview of the current state of knowledge regarding the passive immunization of bNAbs in HIV-1-infected individuals. Main findings: Recent findings from clinical trials have highlighted the potential of bNAbs in the treatment, prevention, and quest for an HIV-1 cure. While monotherapy with a single bNAb is insufficient in maintaining viral suppression and preventing viral escape, ultimately leading to viral rebound, combination therapy with potent, non-overlapping epitope-targeting bNAbs have demonstrated prolonged viral suppression and delayed time to rebound by effectively restricting the emergence of escape mutations, albeit largely in individuals with bNAb-sensitive strains. Additionally, passive immunization with bNAb has provided a “proof of concept” for antibody-mediated prevention against HIV-1 acquisition, although complete prevention has not been obtained. Therefore, further research on the use of bNAbs in HIV-1 treatment and prevention remains imperative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Health, Aarhus University, 8000 Aarhus C, Denmark.
- Clinical Medicine, Department of Infectious Diseases, Aarhus University Hospital, 8200 Aarhus N, Denmark.
- GloHAU, Center of Global Health, Department of Public Health, Aarhus University, 8000 Aarhus C, Denmark.
ORCID-Profile: Christian Morberg Wejse
Förderung
- Danmarks Frie Forskningsfond
- Independent Research Fund Denmark
Zitieren
APA
Thavarajah, J. J., Hønge, B. L., & Wejse, C. M. (2024). The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention. Viruses. https://doi.org/10.3390/v16060911
Vancouver
Thavarajah JJ, Hønge BL, Wejse CM. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention. Viruses. 2024. doi:10.3390/v16060911
BibTeX
@article{Thavarajah2024,
author = {Thavarajah, Jannifer Jasmin and Hønge, Bo Langhoff and Wejse, Christian Morberg},
title = {The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16060911}
}
EUVIMED